Allergy Therapeutics plc (AIM: AGY), the specialist pharmaceutical company focused on allergy vaccination, today announces that its Pollinex Quattro Grass Phase III trial begun in January, the first ever global allergy vaccine programme, has been fully recruited and that the path to marketing approval during 2009 is now clear.
